Basilea Pharmaceutica AG (BSLN.S) Company Profile | Reuters.com
Edition:
United States

Profile: Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

62.40CHF
9:07am EDT
Change (% chg)

CHF0.40 (+0.65%)
Prev Close
CHF62.00
Open
CHF64.70
Day's High
CHF64.70
Day's Low
CHF62.25
Volume
54,921
Avg. Vol
64,117
52-wk High
CHF126.50
52-wk Low
CHF58.80

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Company Address

Basilea Pharmaceutica AG

Grenzacherstrasse 487
BASEL     4058
P: +4161.6061111
F: +4161.6061112

Company Web Links